John Kinsella
Concepts (678)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 897 | 7.350 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 219 | 5.860 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 138 | 4.790 |
Why?
| | Hypertension, Pulmonary | 46 | 2025 | 1980 | 3.300 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 326 | 3.230 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 383 | 2.880 |
Why?
| | Bronchopulmonary Dysplasia | 19 | 2025 | 410 | 2.570 |
Why?
| | Administration, Inhalation | 70 | 2023 | 575 | 2.350 |
Why?
| | Infant, Newborn | 108 | 2026 | 6434 | 2.090 |
Why?
| | Hemodynamics | 41 | 2025 | 1121 | 1.820 |
Why?
| | Infant, Premature | 31 | 2024 | 611 | 1.740 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 183 | 1.730 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 45 | 1.690 |
Why?
| | Vasodilator Agents | 15 | 2022 | 331 | 1.560 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 106 | 1.560 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 182 | 1.450 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 430 | 1.320 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 67 | 1.310 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 111 | 1.200 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 392 | 1.150 |
Why?
| | Respiration, Artificial | 25 | 2019 | 708 | 0.980 |
Why?
| | Intensive Care Units | 7 | 2018 | 916 | 0.980 |
Why?
| | Hypoxia | 19 | 2021 | 1199 | 0.950 |
Why?
| | Oxygen | 21 | 2021 | 995 | 0.880 |
Why?
| | Vascular Resistance | 29 | 2021 | 367 | 0.880 |
Why?
| | Echocardiography | 13 | 2023 | 652 | 0.820 |
Why?
| | Humans | 172 | 2026 | 144957 | 0.790 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 83 | 0.790 |
Why?
| | Gestational Age | 22 | 2024 | 975 | 0.760 |
Why?
| | Lung | 33 | 2023 | 4109 | 0.760 |
Why?
| | Transportation of Patients | 3 | 2020 | 68 | 0.740 |
Why?
| | Critical Care | 8 | 2017 | 697 | 0.720 |
Why?
| | Propofol | 5 | 2024 | 85 | 0.700 |
Why?
| | Bronchoconstriction | 1 | 2020 | 29 | 0.640 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 16 | 0.620 |
Why?
| | Sheep | 40 | 2007 | 880 | 0.620 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 119 | 0.610 |
Why?
| | Anaphylaxis | 1 | 2020 | 102 | 0.590 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 205 | 0.580 |
Why?
| | Heart Atria | 1 | 2020 | 144 | 0.580 |
Why?
| | Fetus | 21 | 2018 | 803 | 0.580 |
Why?
| | Cardiovascular System | 1 | 2020 | 138 | 0.580 |
Why?
| | Vasodilation | 20 | 2005 | 523 | 0.570 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 50 | 0.570 |
Why?
| | Infant | 36 | 2025 | 10039 | 0.570 |
Why?
| | Severity of Illness Index | 15 | 2025 | 2925 | 0.550 |
Why?
| | Hospital Mortality | 6 | 2018 | 1031 | 0.520 |
Why?
| | Heart Ventricles | 3 | 2020 | 760 | 0.520 |
Why?
| | Trachea | 2 | 2018 | 261 | 0.510 |
Why?
| | Critical Illness | 5 | 2017 | 892 | 0.510 |
Why?
| | Early Medical Intervention | 2 | 2014 | 61 | 0.510 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 69 | 0.490 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 102 | 0.490 |
Why?
| | Liver Cirrhosis | 2 | 2015 | 288 | 0.480 |
Why?
| | Animals, Newborn | 18 | 2007 | 902 | 0.480 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 289 | 0.470 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 195 | 0.470 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 17 | 0.470 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.470 |
Why?
| | Female | 83 | 2026 | 78376 | 0.460 |
Why?
| | Blood Coagulation | 1 | 2017 | 268 | 0.460 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1134 | 0.460 |
Why?
| | Umbilical Arteries | 1 | 2015 | 52 | 0.450 |
Why?
| | Morphine | 1 | 2016 | 171 | 0.450 |
Why?
| | Radial Artery | 1 | 2015 | 70 | 0.450 |
Why?
| | Nerve Block | 1 | 2016 | 103 | 0.440 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 160 | 0.440 |
Why?
| | Treatment Outcome | 27 | 2026 | 11695 | 0.440 |
Why?
| | Male | 65 | 2025 | 72406 | 0.420 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 184 | 0.410 |
Why?
| | Vitamin A | 1 | 2013 | 59 | 0.400 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 301 | 0.400 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1563 | 0.390 |
Why?
| | Oxygen Consumption | 3 | 2015 | 724 | 0.390 |
Why?
| | Knowledge Bases | 1 | 2013 | 28 | 0.390 |
Why?
| | Vitamins | 1 | 2013 | 178 | 0.370 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 73 | 0.350 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 120 | 0.350 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 56 | 0.350 |
Why?
| | Retrospective Studies | 27 | 2024 | 17101 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 452 | 0.340 |
Why?
| | Anesthesia, General | 2 | 2005 | 118 | 0.320 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.310 |
Why?
| | Lung Diseases | 6 | 2010 | 787 | 0.310 |
Why?
| | Emergency Medicine | 1 | 2013 | 261 | 0.310 |
Why?
| | Sulfones | 4 | 2013 | 127 | 0.310 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 28 | 0.300 |
Why?
| | Dietary Supplements | 1 | 2013 | 576 | 0.300 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 235 | 0.300 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 265 | 0.290 |
Why?
| | Survival Rate | 14 | 2022 | 2092 | 0.290 |
Why?
| | Dipyridamole | 6 | 1998 | 28 | 0.280 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 214 | 0.280 |
Why?
| | Herniorrhaphy | 2 | 2020 | 74 | 0.280 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 126 | 0.280 |
Why?
| | Nose | 2 | 2008 | 68 | 0.270 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 279 | 0.270 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 10 | 0.270 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 1143 | 0.270 |
Why?
| | Pregnancy | 20 | 2026 | 7191 | 0.260 |
Why?
| | Fluorocarbons | 2 | 1999 | 143 | 0.250 |
Why?
| | Heart Rate, Fetal | 3 | 2026 | 31 | 0.250 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 914 | 0.250 |
Why?
| | Cardiac Output | 8 | 2009 | 179 | 0.250 |
Why?
| | Foreign Bodies | 1 | 2008 | 107 | 0.250 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 118 | 0.250 |
Why?
| | Action Potentials | 1 | 2010 | 507 | 0.250 |
Why?
| | Child | 22 | 2025 | 22657 | 0.240 |
Why?
| | Anticoagulants | 2 | 2024 | 724 | 0.240 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3869 | 0.240 |
Why?
| | Pulmonary Alveoli | 4 | 2022 | 383 | 0.230 |
Why?
| | Thyroidectomy | 2 | 2024 | 91 | 0.230 |
Why?
| | Bradycardia | 1 | 2026 | 59 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 923 | 0.230 |
Why?
| | Atrioventricular Block | 1 | 2026 | 45 | 0.230 |
Why?
| | Animals | 60 | 2022 | 38109 | 0.230 |
Why?
| | Fetal Diseases | 3 | 2026 | 191 | 0.230 |
Why?
| | Piperazines | 3 | 2013 | 381 | 0.220 |
Why?
| | Respiration Disorders | 1 | 2005 | 78 | 0.220 |
Why?
| | Hirudins | 1 | 2024 | 51 | 0.210 |
Why?
| | Respiration | 3 | 2019 | 207 | 0.210 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 19 | 0.210 |
Why?
| | Neck Pain | 1 | 2024 | 30 | 0.210 |
Why?
| | Tracheostomy | 2 | 2024 | 142 | 0.210 |
Why?
| | Antithrombins | 1 | 2024 | 70 | 0.210 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 541 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 104 | 0.200 |
Why?
| | Preoperative Care | 3 | 2017 | 380 | 0.200 |
Why?
| | Heart | 3 | 2019 | 636 | 0.200 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 72 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2032 | 0.190 |
Why?
| | Heparin | 1 | 2024 | 244 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 68 | 0.190 |
Why?
| | Fatal Outcome | 4 | 2012 | 307 | 0.190 |
Why?
| | Double-Blind Method | 4 | 2016 | 2029 | 0.190 |
Why?
| | Nitrites | 1 | 2002 | 89 | 0.190 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 73 | 0.180 |
Why?
| | Antioxidants | 1 | 2006 | 549 | 0.180 |
Why?
| | Prospective Studies | 11 | 2023 | 7997 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 236 | 0.180 |
Why?
| | Respiratory Therapy | 3 | 2003 | 25 | 0.180 |
Why?
| | Incidence | 5 | 2015 | 2883 | 0.170 |
Why?
| | Risk Factors | 12 | 2024 | 10792 | 0.170 |
Why?
| | Prognosis | 7 | 2023 | 4293 | 0.170 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 42 | 0.170 |
Why?
| | Vasoconstriction | 3 | 2005 | 217 | 0.170 |
Why?
| | Precision Medicine | 2 | 2023 | 458 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2024 | 699 | 0.160 |
Why?
| | Emergency Treatment | 1 | 2002 | 124 | 0.160 |
Why?
| | Plethysmography | 1 | 2001 | 109 | 0.160 |
Why?
| | Cardiac Catheterization | 7 | 2025 | 560 | 0.160 |
Why?
| | Fundoplication | 1 | 2020 | 54 | 0.160 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 547 | 0.160 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 32 | 0.160 |
Why?
| | Papio | 6 | 1995 | 85 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 64 | 0.150 |
Why?
| | Blood Pressure | 13 | 2014 | 1769 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.150 |
Why?
| | Fluid Therapy | 2 | 2011 | 147 | 0.150 |
Why?
| | Time Factors | 12 | 2017 | 7183 | 0.150 |
Why?
| | Logistic Models | 6 | 2024 | 2119 | 0.150 |
Why?
| | Middle Aged | 19 | 2019 | 35928 | 0.150 |
Why?
| | Postoperative Complications | 6 | 2017 | 2920 | 0.150 |
Why?
| | Pulmonary Veins | 2 | 1999 | 105 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1721 | 0.150 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 423 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 178 | 0.150 |
Why?
| | Patient Care Team | 2 | 2016 | 689 | 0.140 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1465 | 0.140 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1268 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2118 | 0.140 |
Why?
| | Aged | 15 | 2019 | 25947 | 0.140 |
Why?
| | Treatment Failure | 5 | 2007 | 365 | 0.140 |
Why?
| | United Kingdom | 3 | 2017 | 338 | 0.140 |
Why?
| | Risk | 3 | 2021 | 911 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 189 | 0.140 |
Why?
| | Child, Preschool | 15 | 2025 | 11799 | 0.140 |
Why?
| | Return to Work | 1 | 2017 | 21 | 0.130 |
Why?
| | Adult | 19 | 2026 | 40506 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 88 | 0.130 |
Why?
| | Single-Blind Method | 2 | 2013 | 312 | 0.130 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 120 | 0.130 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 197 | 0.130 |
Why?
| | Heart Rate | 4 | 2009 | 855 | 0.130 |
Why?
| | Thiopental | 1 | 1997 | 13 | 0.130 |
Why?
| | Ondansetron | 1 | 1997 | 19 | 0.130 |
Why?
| | Pneumonectomy | 1 | 2019 | 169 | 0.130 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 320 | 0.130 |
Why?
| | Troponin I | 1 | 2017 | 72 | 0.130 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 179 | 0.130 |
Why?
| | Registries | 6 | 2025 | 2385 | 0.130 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 13 | 0.120 |
Why?
| | Methemoglobin | 2 | 1993 | 24 | 0.120 |
Why?
| | Pulmonary Edema | 1 | 1997 | 106 | 0.120 |
Why?
| | Biological Products | 1 | 2000 | 252 | 0.120 |
Why?
| | Blood Circulation | 3 | 1998 | 44 | 0.120 |
Why?
| | Dyspnea | 1 | 2018 | 251 | 0.120 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 30 | 0.120 |
Why?
| | Capillary Permeability | 1 | 1997 | 134 | 0.120 |
Why?
| | Anesthesia, Local | 1 | 2016 | 25 | 0.120 |
Why?
| | Glycocalyx | 1 | 2016 | 30 | 0.120 |
Why?
| | Follow-Up Studies | 10 | 2019 | 5417 | 0.120 |
Why?
| | Antiemetics | 1 | 1997 | 49 | 0.120 |
Why?
| | Injections, Spinal | 1 | 2016 | 121 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 268 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 113 | 0.120 |
Why?
| | Estradiol | 4 | 2001 | 533 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1540 | 0.120 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 115 | 0.120 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 219 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.120 |
Why?
| | Disease Management | 2 | 2017 | 647 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 248 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 520 | 0.120 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2313 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 732 | 0.120 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 848 | 0.120 |
Why?
| | Employment | 1 | 2017 | 188 | 0.120 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 36 | 0.120 |
Why?
| | Nitroarginine | 10 | 2005 | 57 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 271 | 0.110 |
Why?
| | Chronic Disease | 8 | 2013 | 1813 | 0.110 |
Why?
| | Down Syndrome | 1 | 2022 | 534 | 0.110 |
Why?
| | Length of Stay | 5 | 2017 | 1337 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 845 | 0.110 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 216 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2018 | 548 | 0.110 |
Why?
| | Neutrophils | 3 | 1999 | 1134 | 0.110 |
Why?
| | Faculty, Medical | 1 | 2018 | 303 | 0.110 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 60 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 284 | 0.110 |
Why?
| | Risk Assessment | 4 | 2017 | 3676 | 0.110 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 280 | 0.110 |
Why?
| | Postoperative Care | 1 | 2016 | 288 | 0.110 |
Why?
| | Ventilator Weaning | 2 | 2005 | 39 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 557 | 0.100 |
Why?
| | Ammonia | 2 | 1992 | 65 | 0.100 |
Why?
| | Mothers | 1 | 2020 | 775 | 0.100 |
Why?
| | Vasopressins | 1 | 2014 | 60 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 292 | 0.100 |
Why?
| | Biomarkers | 4 | 2016 | 4275 | 0.100 |
Why?
| | Thrombosis | 1 | 2017 | 393 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 144 | 0.100 |
Why?
| | Pediatrics | 2 | 2019 | 1115 | 0.100 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 9 | 0.100 |
Why?
| | Survival Analysis | 3 | 2009 | 1385 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 126 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 201 | 0.100 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1054 | 0.100 |
Why?
| | Epoprostenol | 3 | 2021 | 131 | 0.090 |
Why?
| | Cyclic GMP | 4 | 2001 | 92 | 0.090 |
Why?
| | Cell Nucleus | 1 | 1996 | 619 | 0.090 |
Why?
| | Coronary Circulation | 2 | 1995 | 136 | 0.090 |
Why?
| | Pilot Projects | 5 | 2024 | 1890 | 0.090 |
Why?
| | Diaphragm | 2 | 2023 | 49 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2016 | 462 | 0.090 |
Why?
| | Hemorrhage | 1 | 2017 | 809 | 0.090 |
Why?
| | Critical Care Nursing | 1 | 2013 | 51 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2015 | 251 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2013 | 249 | 0.090 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 9 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1371 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 9 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2017 | 8279 | 0.090 |
Why?
| | Diseases in Twins | 1 | 2012 | 115 | 0.090 |
Why?
| | Cohort Studies | 5 | 2024 | 5965 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 49 | 0.090 |
Why?
| | Kidney Tubules | 1 | 1992 | 117 | 0.090 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 70 | 0.090 |
Why?
| | Acetylcholine | 5 | 2001 | 206 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2018 | 3608 | 0.080 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 72 | 0.080 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 54 | 0.080 |
Why?
| | Algorithms | 3 | 2013 | 1839 | 0.080 |
Why?
| | Patient Admission | 1 | 2013 | 218 | 0.080 |
Why?
| | Alfentanil | 1 | 2010 | 7 | 0.080 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 12 | 0.080 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 64 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 160 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 204 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.080 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 230 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 178 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1500 | 0.080 |
Why?
| | Thermodilution | 2 | 2005 | 15 | 0.080 |
Why?
| | Disease Models, Animal | 7 | 2007 | 4569 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 965 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 90 | 0.080 |
Why?
| | Communication | 1 | 2016 | 967 | 0.080 |
Why?
| | APACHE | 2 | 2017 | 66 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 940 | 0.080 |
Why?
| | Analysis of Variance | 6 | 2014 | 1311 | 0.070 |
Why?
| | Abdomen | 1 | 2010 | 141 | 0.070 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 62 | 0.070 |
Why?
| | Airway Obstruction | 1 | 1991 | 162 | 0.070 |
Why?
| | Endothelins | 3 | 2000 | 63 | 0.070 |
Why?
| | Vitamin D | 1 | 2012 | 400 | 0.070 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 112 | 0.070 |
Why?
| | Prostaglandins | 2 | 2001 | 94 | 0.070 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 94 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 7 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 514 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 479 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 759 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2434 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 187 | 0.070 |
Why?
| | Scotland | 2 | 2018 | 23 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 304 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1742 | 0.070 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 342 | 0.070 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 50 | 0.060 |
Why?
| | Postoperative Period | 3 | 2016 | 354 | 0.060 |
Why?
| | Acute Disease | 2 | 2005 | 1031 | 0.060 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.060 |
Why?
| | Sex Distribution | 1 | 2008 | 386 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2642 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 109 | 0.060 |
Why?
| | Microspheres | 3 | 1991 | 142 | 0.060 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 9 | 0.060 |
Why?
| | Purines | 3 | 2013 | 187 | 0.060 |
Why?
| | Neoplasms | 2 | 2019 | 2884 | 0.060 |
Why?
| | Piperidines | 1 | 2008 | 217 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 184 | 0.060 |
Why?
| | Swine | 2 | 2003 | 833 | 0.060 |
Why?
| | Umbilical Cord | 1 | 2026 | 91 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 100 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 57 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 826 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 42 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 19 | 0.060 |
Why?
| | Epinephrine | 1 | 2026 | 155 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 601 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 38 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 1141 | 0.060 |
Why?
| | Prenatal Care | 1 | 2007 | 307 | 0.050 |
Why?
| | Signal Transduction | 3 | 2005 | 5233 | 0.050 |
Why?
| | Electric Impedance | 1 | 2005 | 111 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 298 | 0.050 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 52 | 0.050 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 67 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2947 | 0.050 |
Why?
| | Amides | 1 | 2005 | 101 | 0.050 |
Why?
| | Electroencephalography | 1 | 2008 | 551 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 783 | 0.050 |
Why?
| | Aging | 2 | 1992 | 1966 | 0.050 |
Why?
| | Carbon Dioxide | 4 | 1999 | 242 | 0.050 |
Why?
| | Cesarean Section | 1 | 2026 | 224 | 0.050 |
Why?
| | Rats | 7 | 2005 | 5614 | 0.050 |
Why?
| | Carcinoma | 2 | 2016 | 228 | 0.050 |
Why?
| | Home Nursing | 1 | 2003 | 23 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1358 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 89 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 636 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 522 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 261 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 269 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 64 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 449 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 310 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 93 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 130 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 12 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 142 | 0.050 |
Why?
| | Age Factors | 3 | 2016 | 3335 | 0.050 |
Why?
| | Stomach | 1 | 2002 | 109 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 88 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2022 | 193 | 0.040 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.040 |
Why?
| | Analgesics | 1 | 2024 | 231 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 166 | 0.040 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 346 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3164 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 202 | 0.040 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 48 | 0.040 |
Why?
| | Uterus | 1 | 2002 | 226 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5872 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 381 | 0.040 |
Why?
| | Muscle, Smooth | 2 | 2000 | 153 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 26 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 66 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 92 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 151 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 14 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 26 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6053 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 873 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 129 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2880 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 204 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 47 | 0.040 |
Why?
| | Patient Transfer | 1 | 2002 | 206 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 208 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 22453 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 248 | 0.040 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 5 | 0.040 |
Why?
| | Leukocyte Count | 2 | 1997 | 316 | 0.030 |
Why?
| | Blood Vessels | 1 | 2000 | 171 | 0.030 |
Why?
| | Drug Synergism | 2 | 1998 | 357 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 457 | 0.030 |
Why?
| | Acidosis | 2 | 1992 | 105 | 0.030 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 18 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 349 | 0.030 |
Why?
| | Body Weight | 2 | 2005 | 978 | 0.030 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 55 | 0.030 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1718 | 0.030 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 63 | 0.030 |
Why?
| | Occipital Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Frontal Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 145 | 0.030 |
Why?
| | Cephalometry | 1 | 1997 | 30 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 642 | 0.030 |
Why?
| | Growth | 1 | 1997 | 49 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2852 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 144 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 136 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 24 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2931 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 43 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 23 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 19 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 194 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 297 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 262 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 321 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 32 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 121 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 202 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 75 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 38 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 130 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 39 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 719 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 282 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1496 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 152 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 130 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 188 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1187 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 651 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 237 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 160 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1495 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 81 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 222 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 276 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 216 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 37 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 162 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 275 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 418 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 675 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2191 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 430 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 328 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 119 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 220 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 53 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 414 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 164 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 220 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 46 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 153 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 413 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 695 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 383 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 42 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1993 | 79 | 0.020 |
Why?
| | Area Under Curve | 1 | 2014 | 331 | 0.020 |
Why?
| | Schools, Medical | 1 | 2015 | 157 | 0.020 |
Why?
| | Stress, Mechanical | 3 | 2001 | 494 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1048 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 1768 | 0.020 |
Why?
| | Reference Values | 3 | 2002 | 798 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2016 | 303 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 675 | 0.020 |
Why?
| | Hypertension | 1 | 2002 | 1264 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 339 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 511 | 0.020 |
Why?
| | Young Adult | 1 | 2009 | 14126 | 0.020 |
Why?
| | DNA | 2 | 1998 | 1464 | 0.020 |
Why?
| | Lactic Acid | 1 | 2014 | 302 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2836 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 1992 | 3 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 73 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 116 | 0.020 |
Why?
| | Child Development | 1 | 1997 | 484 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 615 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 23 | 0.020 |
Why?
| | United States | 3 | 2012 | 15988 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 338 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 980 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1888 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 109 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 39 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2941 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 205 | 0.020 |
Why?
| | Quality of Life | 2 | 2017 | 3192 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 74 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1077 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 381 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1733 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 37 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1258 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 51 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 169 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 983 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 150 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 770 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 195 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2114 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 285 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 25 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2832 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 149 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 24 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 77 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 41 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 299 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 131 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 81 | 0.020 |
Why?
| | Burns | 2 | 1991 | 377 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 124 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 395 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 16 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 225 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 30 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 368 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 350 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 47 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 38 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4155 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 9 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 463 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 48 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1003 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 636 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 48 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 137 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 281 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 866 | 0.010 |
Why?
| | RNA, Viral | 1 | 1990 | 688 | 0.010 |
Why?
| | Proteins | 1 | 1992 | 1022 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1660 | 0.010 |
Why?
| | Thoracic Diseases | 1 | 2005 | 11 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 198 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2005 | 36 | 0.010 |
Why?
| | Phosphates | 1 | 1986 | 180 | 0.010 |
Why?
| | Oscillometry | 1 | 2005 | 35 | 0.010 |
Why?
| | Manometry | 1 | 2005 | 97 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 85 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 127 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 108 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4564 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 392 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1137 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 93 | 0.010 |
Why?
| | Time | 1 | 2003 | 86 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 983 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 524 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 4 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 4 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 80 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 218 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 16 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 737 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 54 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 83 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 58 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 27 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 535 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 151 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 26 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1244 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 427 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 663 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 66 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 173 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 135 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 43 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 15 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 83 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 154 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 165 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 165 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 313 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 674 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 162 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 401 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1184 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 501 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 46 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2540 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 14 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 660 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 20 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 28 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 84 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 89 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 13 | 0.010 |
Why?
| | Masks | 1 | 1998 | 70 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1490 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 277 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 183 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 117 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 906 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 189 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 178 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 541 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 438 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 76 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 75 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 151 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 255 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 174 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 30 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 41 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 41 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 197 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 56 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 79 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 82 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 280 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 75 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 77 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 75 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 6 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 24 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2157 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 509 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 391 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 472 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 250 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 358 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 122 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 553 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 25 | 0.000 |
Why?
| | Macrophage Activation | 1 | 1991 | 193 | 0.000 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 36 | 0.000 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 187 | 0.000 |
Why?
| | Gene Amplification | 1 | 1990 | 121 | 0.000 |
Why?
| | Cell Count | 1 | 1990 | 321 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 298 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 931 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 316 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 27 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 22 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1054 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 538 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 561 | 0.000 |
Why?
| | Skin | 1 | 1990 | 758 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 760 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1511 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|